ALXO Stock Discussion
ALX Oncology Holdings Inc. Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Oncology Cancer Immunotherapy Acute Myeloid Leukemia Epidermal Growth Factor Receptor Carcinoma Myelodysplastic Syndrome Syndromes Treatment Of Myelodysplastic Syndrome
Recent Comments
- TraderMike on BOOT
- Dr_Duru on BOOT
- TraderMike on Stochastic Reached Oversold
- SuccessfulGrasshopper897 on Stochastic Reached Oversold
- Cos3 on Adding float as advanced filter criteria?
From the Blog
Popular Now
Featured Articles